Page 141 - 2018_10-Haematologica-web

Impact of the eGVHD App on GvHD assessment
their requirements in the near future to allow for this dynamic progress of the cyber world, even for healthcare applications. This is, in fact, probably one of the most chal- lenging aspects of integrating eTools in modern models of care.21
Compared to other smaller-scaled initiatives, which have shown successful implementation of eHealth technologies in local electronic medical record systems14 or specific research programs12,13 to assess GvHD, the eGVHD App is now widely available (www.uzleuven.be/egvhd) for all health- care professionals who wish to obtain bedside user-friendly assistance in their GvHD assessment, and to improve their expertise and/or the uniformity of their GvHD data collec- tion, both in daily practice and in clinical trials. Further val- idation regarding its usefulness and scalability will, there- fore, be able to rely on the analysis of the real-life data gen- erated by downloads and feedback from users, based on implementation research principles. If results are convinc- ing, the next steps could include the direct integration of eGVHD App-generated data in larger registry databases and electronic medical record systems to circumvent the need to produce separate reports and repeat data entry.
Such developments will require further reflections on how to achieve optimal control of the quality of the entered data and guarantee its privacy protection according to local laws.
In conclusion, the eGVHD App shows superior accuracy for the GvHD assessment of clinical vignettes compared to usual care and has, therefore, the potential to improve the quality of GvHD data in clinical research and practice. In the era of electronic medical files, ‘big data’ and increased connectivity, e-Tools are likely to become widespread in our daily practice and could even gradually turn the individ- ual patient into his or her own data manager and most involved advocate. Only time and continuous research will tell whether such tools can be effectively used in clinical practice and whether healthcare professionals are ready to accept IT assistance to solve some of the practical issues.
Acknowledgments
The authors would like to thank all of the participating hospitals for their collaboration and enthusiasm in validating the eGVHD App. We are also very grateful for the financial support of SOFHEA vzw (Sociaal Fonds voor Hematologische Aandoeningen) for this project.
References
1. Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018 Jun 5. [Epub ahead of print PMID: 29872128].
2. Carpenter PA, Logan BR, Lee SJ, et al. Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2016;22(3):S50-S52.
3. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host dis- ease after unrelated donor marrow trans- plantation: a grading algorithm versus blind- ed expert panel review. Biol Blood Marrow Transplant. 2003;9(8):512-518.
4. Schoemans H, Goris K, Durm RV, et al. Development, preliminary usability and accuracy testing of the EBMT 'eGVHD App' to support GvHD assessment accord- ing to NIH criteria-a proof of concept. Bone Marrow Transplant. 2016;51(8):1062- 1065.
5. Schoemans HM, Goris K, Van Durm R, et al. Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. Bone Marrow Transplant. 2018;53(4):490- 494.
6. Mitchell SA, Jacobsohn D, Thormann Powers KE, et al. A multicenter pilot evalua- tion of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility,
interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant. 2011;17(11):1619-1629.
7. Duarte RF, Greinix H, Rabin B, et al. Uptake and use of recommendations for the diagno- sis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow Transplant. 2014;49(1):49-54.
8. Harris AC, Young R, Devine S, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4-10.
9. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A- matched sibling donors. Transplantation. 1974;18(4):295-304.
11. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12): 945-956.
12. Levine JE, Hogan WJ, Harris AC, et al. Improved accuracy of acute graft-versus- host disease staging among multiple centers. Best Pract Res Clin Haematol. 2014;27(3- 4):283-287.
13. Mancini G, Frulla R, Vico M, e al. A new software for evaluating scoring and response in cGVHD according to the new NIH crite-
ria. Bone Marrow Transplant. 2016;51(Issue
S1):S183.
14. Dierov Djamilia CC, Fatmi S, Mosesso K, et
al . Establishing a standardized system to capture chronic graft-versus-host disease (GVHD) data in accordance to the national institutes (NIH) consensus criteria. Bone Marrow Transplant. 2017;52 (Suppl 1):S102 (abstract O157).
15. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119-4126.
16. Martin PJ, Schoch G, Fisher L, et al. A retro-
spective analysis of therapy for acute graft- versus-host disease: initial treatment. Blood. 1990;76(8):1464-1472.
17. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16(12): 1611-1628.
18. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus- host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-999.
19. MacMillan ML, Robin M, Harris AC, et al. A Refined Risk Score for Acute Graft-versus- Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant- Related Mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767.
20. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus- host disease. Biol Blood Marrow Transplant. 2002;8(8):444-452.
21. Tuckson RV, Edmunds M, Hodgkins ML. Telehealth. N Engl J Med. 2017;377(16): 1585-1592.
haematologica | 2018; 103(10)
1707